Literature DB >> 30218244

Drivers of Cost for Pancreatic Surgery: It's Not About Hospital Volume.

Sarah B Bateni1, Jennifer L Olson1, Jeffrey S Hoch2, Robert J Canter1, Richard J Bold3.   

Abstract

BACKGROUND: Outcomes for pancreatic resection have been studied extensively due to the high morbidity and mortality rates, with high-volume centers achieving superior outcomes. Ongoing investigations include healthcare costs, given the national focus on reducing expenditures. Therefore, we sought to evaluate the relationships between pancreatic surgery costs with perioperative outcomes and volume status.
METHODS: We performed a retrospective analysis of 27,653 patients who underwent elective pancreatic resections from October 2013 to June 2017 using the Vizient database. Costs were calculated from charges using cost-charge ratios and adjusted for geographic variation. Generalized linear modeling adjusting for demographic, clinical, and operation characteristics was performed to assess the relationships between cost and length of stay, complications, in-hospital mortality, readmissions, and hospital volume. High-volume centers were defined as hospitals performing ≥ 19 operations annually.
RESULTS: The unadjusted mean cost for pancreatic resection and corresponding hospitalization was $20,352. There were no differences in mean costs for pancreatectomies performed at high- and low-volume centers [- $1175, 95% confidence interval (CI) - $3254 to $904, p = 0.27]. In subgroup analysis comparing adjusted mean costs at high- and low-volume centers, there was no difference among patients without an adverse outcome (- $99, 95% CI - $1612 to 1414, p = 0.90), one or more adverse outcomes (- $1586, 95% CI - $4771 to 1599, p = 0.33), or one or more complications (- $2835, 95% CI - $7588 to 1919, p = 0.24).
CONCLUSIONS: While high-volume hospitals have fewer adverse outcomes, there is no relationship between surgical volume and costs, which suggests that, in itself, surgical volume is not an indicator of improved healthcare efficiency reflected by lower costs. Patient referral to high-volume centers may not reduce overall healthcare expenditures for pancreatic operations.

Entities:  

Mesh:

Year:  2018        PMID: 30218244      PMCID: PMC6367004          DOI: 10.1245/s10434-018-6758-1

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  2 in total

1.  Is Improved Survival in Early-Stage Pancreatic Cancer Worth the Extra Cost at High-Volume Centers?

Authors:  Lauren M Perry; Sarah B Bateni; Richard J Bold; Jeffrey S Hoch
Journal:  J Am Coll Surg       Date:  2021-03-22       Impact factor: 6.113

2.  Risk factors and socio-economic burden in pancreatic ductal adenocarcinoma operation: a machine learning based analysis.

Authors:  Yijue Zhang; Sibo Zhu; Zhiqing Yuan; Qiwei Li; Ruifeng Ding; Xunxia Bao; Timing Zhen; Zhiliang Fu; Hailong Fu; Kaichen Xing; Hongbin Yuan; Tao Chen
Journal:  BMC Cancer       Date:  2020-11-27       Impact factor: 4.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.